REG - ValiRx PLC - ValiRx Awarded Grant from Open University

ValiRxAnnouncement

07/08/2025 11:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250807:nRSG4259Ua&default-theme=true

RNS Number : 4259U  ValiRx PLC  07 August 2025

7 August 2025

ValiRx PLC

("ValiRx" or the "Company")

 

ValiRx Awarded Grant from Open University

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on
early-stage cancer therapeutics and women's health, provides the following
update from its wholly owned subsidiary Inaphaea BioLabs Limited ("Inaphaea").

Inaphaea is pleased to confirm it has been awarded a Knowledge Transfer
Voucher ("KTV") to partner with The Open University ("OU"). This funding will
be used to perform advanced imaging-based analysis of Inaphaea biolab's
patient derived cell models. The project, which will run from 1st August 2025
to 30(th) September 2026, will utilise The Open University's expertise in
biophysical and machine learning approaches for predicting self-organisation
in tissues to build algorithms to assess drug responses in tumour spheroids.
The three primary aims of the program are to carry out confocal microscopy of
tumoroids provided by Inaphaea; to validate the use of the OU developed
contractile network dipole orientation ("CONDOR") simulations to model these
tumoroids and to strengthen links with Inaphaea for future grant applications.

 

 Mark Eccleston, CEO of ValiRx commented "We are grateful to The Open
University for its continued support across multiple ValiRx companies as we
work with leading academic experts to advance our technical capabilities
around advanced PDC models and cell-based testing. This is the third award we
have received and is very timely given recent updates to the FDA Modernization
Act 2.0, which expands regulatory safety and efficacy testing options to
include 3D cell cultures as a viable alternative to animal testing. We have
built multiple partnerships to expand and develop our capabilities in this
area to deliver better products and services through Inaphaea and progress
assets faster and further down the pipeline with in-house resources,
ultimately leading to better therapeutic candidates from our various SPVs."

Jim Hague, Senior Lecturer at the Faculty of Science, Technology, Engineering
& Mathematics, The Open University commented "In partnership with
Inaphaea, we want to improve spheroid use as models for drug-development, with
a focus on treatments for major cancers (an area of significant interest for
our partner, especially triple-negative breast, colorectal and prostate
cancers). Our biophysical and machine learning solutions allow us to obtain
key additional information about spheroid structure and cell organisation,
vital to assess the health of the spheroid tissue. Therefore, addressing an
unmet need for analytic tools to understand how accurately spheroid responses
to drug candidates represent real tissues."

 

The Directors of the Company take responsibility for this announcement.

*** ENDS ***

Engage with the ValiRx management team directly by asking questions, watching
video
summaries and seeing what other shareholders have to say. Navigate to
our Interactive Investor
hub here: https://valirx.com/s/cc8ef3

For more information, please contact:

 Investor questions on this announcement           https://valirx.com/link/PljYke

 We encourage all investors to share questions

 on this announcement via our investor hub
 ValiRx plc                                        Tel: +44 115 784 0026

                                                   www.valirx.com (http://www.valirx.com)

 Dr Mark Eccleston, CEO                            Mark.Eccleston@valirx.com

 Cairn Financial Advisers LLP (Nominated Adviser)  Tel: +44 (0) 20 7213 0880

 Liam Murray / Ludovico Lazzaretti

 Shard Capital Partners LLP (Sole Broker)          Tel: +44 (0) 20 7186 9000

 Damon Heath

 V Formation (Public Relations)                    +44 (0) 115 787 0206

                                                   www.vformation.biz (http://www.vformation.biz)

 Lucy Wharton - Senior PR Executive

 Sue Carr - Director                               lucy@vformation.biz

                                                   sue@vformation.biz

Subscribe to our news alert service: https://valirx.com/s/f298d1
(https://valirx.com/s/f298d1)

 

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics
and women's health, accelerating the translation of innovative science into
impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for
enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development,
the team at ValiRx selects and incubates promising novel drug candidates and
guides them through an optimised process of development, from pre-clinical
studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and
commercial domains, with the aim of achieving a more streamlined, less costly,
drug development process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for science to
advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006
and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com (http://www.valirx.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUBSKRVKUWRRR